Just now, the US Preventive Services Task Force (USPSTF) has updated and issued a new version of the aspirin recommendation statement for the prevention of cardiovascular disease (pictured above). Based on the newly obtained clinical research evidence in recent years, the experts of the working group revised the 2016 version of the recommendation statement, and put forward the latest recommendations for the application of aspirin in the primary prevention of atherosclerotic cardiovascular disease (ASCVD).
Through a systematic review of the existing literature, the panel assessed the effects of aspirin for primary prevention on cardiovascular events (myocardial infarction and stroke), cardiovascular mortality, and overall mortality in people without a history of cardiovascular disease. The effect of aspirin on mortality and the risk of adverse events (particularly bleeding complications) from aspirin use and the role of aspirin in the prevention of colorectal cancer were also assessed to comprehensively evaluate the use of aspirin for cardiovascular disease and colorectal cancer level 1 Net benefit of prevention.
The object of this opinion statement is to have no symptoms and signs of cardiovascular disease, no history of cardiovascular disease, and no high risk factors for bleeding (history of gastrointestinal ulcers, recent bleeding events, use of drugs that increase the risk of bleeding, and other relevant clinical conditions) in adults ≥ 40 years of age.
The review concluded that the net benefit of aspirin for primary prevention of cardiovascular disease in adults aged 40-59 years with a 10-year cardiovascular risk ≥10% was small. There was no net benefit of initiating aspirin for primary prevention in adults ≥60 years of age.
Based on the above results, the USPSTF panel recommends the following: 10-year cardiovascular disease ≥10% in adults aged 40-59 years, the net benefit of using aspirin for primary cardiovascular disease prevention The benefit is small. Patients without risk factors for bleeding and patients willing to take low-dose aspirin for a long time may benefit. Initiation of aspirin for primary prevention of cardiovascular disease is not recommended for persons ≥60 years old.
Follow the WeChat public account “Guo Yifang Frontier” to receive the latest academic progress information in this field as soon as possible.
(Guo Yifang, Hebei Provincial People’s Hospital)